William Whitford,
Life Science Strategic Solutions Leader,
DPS Group
Bill Whitford has joined the DPS consulting team as the Life Science Strategic Solutions Leader. He will be assisting in supporting innovative therapeutics and developing life science solutions. He had been an R&D Leader, developing and commercializing over 40 distinct products supporting diverse biomedical and biomanufacturing applications. He now enjoys serving on such boards and committees as LabTwin’s Lab of the Future Council and the Editorial Advisory Board of BioProcess International. Bill’s recent publications involve Industry 4.0 and digitalization, bioreactor model-based prediction and control, bioprocess intensification, continuous biomanufacturing, applications in cell and gene therapy, exosome production and isolation, 3D bioprinting, theranostics and bioIntelligent manufacturing.
Equipment and Facility Considerations for 3D Bioprinting Based Production
Friday, 19 March 2021 at 11:30
Add to Calendar ▼2021-03-19 11:30:002021-03-19 12:30:00Europe/LondonEquipment and Facility Considerations for 3D Bioprinting Based Production3D-Bioprinting 2021 in BostonBostonSELECTBIOenquiries@selectbiosciences.com
Both 3D bioprinting technologies and applications are developing at an extremely fast pace. Diverse analytical and diagnostic products made using bioprinting technologies include microfluidic devices, organ-on-a-chip systems, and 3D in vitro tissue models for both drug research and clinical diagnostics. Therapeutic products are also beginning to be developed and these include bioprinted patches, tissues systems, and even organs. For the regulation of these products, the US FDA has spoken on the issue of the certification of 3D printed medical devices and have indicated they intend to codify issues related to bioprinting. However, 3D printing technology is so dynamic that basic questions remain regarding practical and comprehensive requirements for the manufacturing of 3D bioprinted products or 3DBP (and personalized 3DBP), diagnostic and therapeutic materials, devices and cell therapies. Facility and work-flow solutions are dependent upon many process design and compliance factors. As technological and regulatory obstacles are being removed, the development of biomanufacturing operations raises new considerations. These considerations will include whether the 3DBP is traditional, patient-specific or customizable as well as hospital-made or mass produced. The following will therefore include current thoughts on materials, equipment, facilities and workflows for the production and manufacturing of 3DBP.
Add to Calendar ▼2021-03-18 00:00:002021-03-19 00:00:00Europe/London3D-Bioprinting 20213D-Bioprinting 2021 in BostonBostonSELECTBIOenquiries@selectbiosciences.com
Add to Calendar ▼2021-03-19 11:30:002021-03-19 12:30:00Europe/LondonEquipment and Facility Considerations for 3D Bioprinting Based Production3D-Bioprinting 2021 in BostonBostonSELECTBIOenquiries@selectbiosciences.com
